BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sagimet Biosciences Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Sagimet Biosciences Inc.'s drugs 
 run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07863193-6740@assetmemo.bio
DTSTAMP:20261121T005947Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Denifanstat: Phase 3 readout est. (NCT07863193)
DESCRIPTION:Denifanstat\, phase 3.\nStudy: Phase 3 Study of Denifanstat in 
 Participants With Moderate to Severe Acne (AURORA)\nEstimated primary comp
 letion: August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 denifanstat#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07863193
URL:https://assetmemo.bio/drug/denifanstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
